Chang Carmen

10% owner Chang Carmen purchased 207,100 shares of KRRO at $11.11 for $2.3M; 8 other insiders also bought within 14 days amid -77.6% decline from 52-week high.

Chang Carmen, a 10% owner, purchased 207,100 shares at $11.11 on 2026-03-10, increasing holdings from 1,090,793 to 1,297,893 shares (+19.0%). This transaction occurs as the stock trades -77.6% from its 52-week high of $51.36, and notably, 8 other insiders also bought within the past 14 days, forming a cluster buy pattern. While the company posted strong revenue growth of +181.5% year-over-year and recently reported $1.1M in quarterly revenue, it remains unprofitable with a net loss of $-18.1M over its most recent full fiscal year. Chang's prior buy at KRRO in April 2024 returned -18.6% over 90 days, suggesting this ticker has not been a reliable vehicle despite his cross-ticker track record showing a +2.9% average 90-day return across other holdings. The confluence of cluster buying activity at a depressed valuation alongside persistent unprofitability warrants close observation of whether this represents conviction-driven accumulation or a potential signal of mispricing in a volatile biotech name.

10% Owner Carmen Chang bought 937,500 shares of SGP at $16.00 ($15.0M) on 2026-02-09; cluster pattern with 14 other insiders.

Chang Carmen, a 10% owner, purchased 937,500 shares at $16.00 for $15,000,000.00 in a large single transaction, increasing her holdings from 419,763 shares to 1,357,263 shares (+223.3%). This purchase occurred in the context of a broader cluster pattern, with 14 other insiders also buying within the past 14 days, suggesting coordinated accumulation activity. The stock has traded at $27.55 as of 2026-02-11 (4 days post-transaction), though 52-week metrics are not yet meaningful given the recent listing. The filing includes a derivative-conversion transaction (Table II), indicating the reported shares_after may not represent Chang's complete position; investors should monitor derivative holdings separately as that table populates.

10% owner Carmen Chang buys 500,000 MBX shares for $8.0M at $16.00 amid 14-insider cluster buy within 14 days

Carmen Chang, a 10% owner of MBX Biosciences, purchased 500,000 shares at $16.00 on 2024-09-16, just 3 trading days after the company's recent listing, for a total of $8,000,000. This transaction increased his holdings by +16.1% to 3,614,486 shares. The filing contains a derivative-conversion transaction (Table II), meaning his full position extends beyond the Table I shares shown here and should not be treated as a complete stake representation. Most significantly, this buy is part of a cluster pattern in which 14 other insiders purchased shares within the same 14-day window, suggesting broad-based insider participation at price levels near the IPO. The current market price of $21.50 represents a 34.4% premium to the transaction price, though the stock's very recent listing status limits the value of longer-term price context. The concurrence of multiple insider buys at IPO pricing warrants investor scrutiny of the transaction cluster itself and the underlying company fundamentals driving the synchronized insider activity.